Signature Dx to Launch Colorectal Cancer IVD in Late-'10, Early-'11

The assay evaluate 202 genes known to be active in leukocytes in the presence of colorectal tumor formation. It has 90-percent sensitivity for all four colorectal cancer stages and 88-percent specificity.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.